{"title": "Regulatory Classification of Pharmaceutical Co-Crystals", "author": "Center; Research", "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-classification-pharmaceutical-co-crystals", "hostname": "fda.gov", "description": "Pharmaceutical Quality/CMC", "sitename": "FDA", "date": "2020-04-17", "cleaned_text": "GUIDANCE DOCUMENT Regulatory Classification of Pharmaceutical Co-Crystals February 2018 - Docket Number: [FDA-2011-D-0800](https://www.regulations.gov/docket/FDA-2011-D-0800) - Issued by: - Guidance Issuing OfficeCenter for Drug Evaluation and Research This guidance provides applicants planning to submit new drug applications (NDAs) and abbreviated new drug applications (ANDAs) with information on the appropriate regulatory classification of pharmaceutical co-crystal solid-state forms. This guidance also provides information about the data that applicants should submit to support the appropriate classification of a co-crystal as well as the regulatory implications of the classification. Submit Comments You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5)) If unable to submit comments online, please mail written comments to: Dockets Management Food and Drug Administration 5630 Fishers Lane, Rm 1061 Rockville, MD 20852 All written comments should be "}